Sandoz has announced the launch of a generic version of oncology treatment Alimta (pemetrexed) in 11 countries across Europe, including Germany, Switzerland, Netherlands and Spain. And according to the company, its ready-to-dilute 1,000mg formulation of the generic, indicated for patients with non-squamous non-small cell lung cancer, is expected to be launched further across Europe throughout the second half of 2021.
Sandoz Launches Pemetrexed In 11 European Countries
Oncology Generic Launch Markets Include Germany, Switzerland, Netherlands And Spain
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
